Karolinska Development AB (publ) (KDEV.ST)
SEK 1.07
(3.5%)
SEK 1.07
(3.5%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.25 Billion SEK | 0.54% |
| 2022 | 1.25 Billion SEK | 12.83% |
| 2021 | 1.1 Billion SEK | 24.63% |
| 2020 | 890.08 Million SEK | -23.71% |
| 2019 | 1.16 Billion SEK | 46.87% |
| 2018 | 794.38 Million SEK | 19.77% |
| 2017 | 663.25 Million SEK | 51.32% |
| 2016 | 438.32 Million SEK | -28.67% |
| 2015 | 614.46 Million SEK | -64.07% |
| 2014 | 1.71 Billion SEK | -9.78% |
| 2013 | 1.89 Billion SEK | -14.41% |
| 2012 | 2.21 Billion SEK | -5.58% |
| 2011 | 2.34 Billion SEK | 32.26% |
| 2010 | 1.77 Billion SEK | -13.0% |
| 2009 | 2.03 Billion SEK | 22.51% |
| 2008 | 1.66 Billion SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.26 Billion SEK | 0.14% |
| 2024 Q2 | 1.24 Billion SEK | -1.25% |
| 2023 Q1 | 1.22 Billion SEK | -2.42% |
| 2023 Q3 | 1.25 Billion SEK | 0.86% |
| 2023 Q2 | 1.24 Billion SEK | 2.05% |
| 2023 Q4 | 1.25 Billion SEK | 0.1% |
| 2023 FY | 1.25 Billion SEK | 0.54% |
| 2022 Q3 | 1.24 Billion SEK | -3.64% |
| 2022 Q4 | 1.25 Billion SEK | 0.81% |
| 2022 FY | 1.25 Billion SEK | 12.83% |
| 2022 Q1 | 1.31 Billion SEK | 18.16% |
| 2022 Q2 | 1.28 Billion SEK | -1.7% |
| 2021 Q4 | 1.1 Billion SEK | -1.58% |
| 2021 FY | 1.1 Billion SEK | 24.63% |
| 2021 Q1 | 863.77 Million SEK | -2.96% |
| 2021 Q2 | 1.08 Billion SEK | 25.34% |
| 2021 Q3 | 1.12 Billion SEK | 4.1% |
| 2020 Q1 | 1 Billion SEK | -13.83% |
| 2020 Q2 | 1 Billion SEK | -0.37% |
| 2020 Q3 | 818.15 Million SEK | -18.32% |
| 2020 Q4 | 890.08 Million SEK | 8.79% |
| 2020 FY | 890.08 Million SEK | -23.71% |
| 2019 FY | 1.16 Billion SEK | 46.87% |
| 2019 Q2 | 814.94 Million SEK | 3.02% |
| 2019 Q4 | 1.16 Billion SEK | 46.62% |
| 2019 Q1 | 791.08 Million SEK | -0.42% |
| 2019 Q3 | 795.7 Million SEK | -2.36% |
| 2018 Q4 | 794.38 Million SEK | 11.68% |
| 2018 FY | 794.38 Million SEK | 19.77% |
| 2018 Q2 | 693.44 Million SEK | 6.25% |
| 2018 Q3 | 711.28 Million SEK | 2.57% |
| 2018 Q1 | 652.65 Million SEK | -1.6% |
| 2017 Q3 | 618.62 Million SEK | 50.51% |
| 2017 Q4 | 663.25 Million SEK | 7.21% |
| 2017 FY | 663.25 Million SEK | 51.32% |
| 2017 Q1 | 424.42 Million SEK | -3.17% |
| 2017 Q2 | 411.02 Million SEK | -3.16% |
| 2016 FY | 438.32 Million SEK | -28.67% |
| 2016 Q1 | 523.87 Million SEK | -14.74% |
| 2016 Q2 | 454.05 Million SEK | -13.33% |
| 2016 Q4 | 438.32 Million SEK | -2.48% |
| 2016 Q3 | 449.47 Million SEK | -1.01% |
| 2015 Q3 | 727.52 Million SEK | -2.75% |
| 2015 Q1 | 1.79 Billion SEK | 5.08% |
| 2015 FY | 614.46 Million SEK | -64.07% |
| 2015 Q4 | 614.46 Million SEK | -15.54% |
| 2015 Q2 | 748.08 Million SEK | -58.37% |
| 2014 Q4 | 1.71 Billion SEK | 3.58% |
| 2014 Q2 | 1.77 Billion SEK | -9.6% |
| 2014 Q1 | 1.96 Billion SEK | 3.39% |
| 2014 Q3 | 1.65 Billion SEK | -6.81% |
| 2014 FY | 1.71 Billion SEK | -9.78% |
| 2013 Q4 | 1.89 Billion SEK | -5.63% |
| 2013 Q2 | 2.09 Billion SEK | 0.29% |
| 2013 Q1 | 2.09 Billion SEK | -5.49% |
| 2013 FY | 1.89 Billion SEK | -14.41% |
| 2013 Q3 | 2 Billion SEK | -4.32% |
| 2012 Q2 | 2.15 Billion SEK | -4.46% |
| 2012 Q1 | 2.25 Billion SEK | -3.99% |
| 2012 FY | 2.21 Billion SEK | -5.58% |
| 2012 Q4 | 2.21 Billion SEK | 2.48% |
| 2012 Q3 | 2.16 Billion SEK | 0.44% |
| 2011 FY | 2.34 Billion SEK | 32.26% |
| 2011 Q4 | 2.34 Billion SEK | 0.0% |
| 2010 FY | 1.77 Billion SEK | -13.0% |
| 2009 FY | 2.03 Billion SEK | 22.51% |
| 2008 FY | 1.66 Billion SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -962.383% |
| Ziccum AB (publ) | 14.97 Million SEK | -8304.976% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -6179.093% |
| BioArctic AB (publ) | 1.18 Billion SEK | -6.097% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -1917.399% |
| Mendus AB (publ) | 755.95 Million SEK | -66.465% |
| Genovis AB (publ.) | 288.85 Million SEK | -335.646% |
| Intervacc AB (publ) | 259.61 Million SEK | -384.723% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -2899.102% |
| Active Biotech AB (publ) | 44 Million SEK | -2759.984% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -351.45% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -1924.702% |
| Aptahem AB (publ) | 63.02 Million SEK | -1896.659% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | -153.581% |
| Kancera AB (publ) | 65.64 Million SEK | -1817.025% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -258.176% |
| Fluicell AB (publ) | 9.34 Million SEK | -13373.158% |
| Saniona AB (publ) | 64.14 Million SEK | -1861.856% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -3644.994% |
| Biovica International AB (publ) | 131.4 Million SEK | -857.623% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -2274.999% |
| AcouSort AB (publ) | 34.51 Million SEK | -3546.142% |
| Xintela AB (publ) | 18.39 Million SEK | -6740.951% |
| Abliva AB (publ) | 87.49 Million SEK | -1338.18% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | -65.534% |
| OncoZenge AB (publ) | 20.34 Million SEK | -6086.79% |
| Amniotics AB (publ) | 26.08 Million SEK | -4724.017% |
| 2cureX AB (publ) | 16.62 Million SEK | -7469.281% |
| CombiGene AB (publ) | 120.61 Million SEK | -943.34% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -20607.471% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 33.788% |
| Camurus AB (publ) | 1.9 Billion SEK | 34.04% |
| Corline Biomedical AB | 100.1 Million SEK | -1157.073% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -610.471% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -795.035% |
| I-Tech AB | 152.44 Million SEK | -725.484% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | -23.609% |
| Cyxone AB (publ) | 43.65 Million SEK | -2782.586% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -1499.137% |
| Biosergen AB | 7.2 Million SEK | -17375.253% |
| Cantargia AB (publ) | 223.71 Million SEK | -462.506% |
| NextCell Pharma AB | 81.28 Million SEK | -1448.067% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | -64.439% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -4070.588% |
| Nanologica AB (publ) | 77.42 Million SEK | -1525.222% |
| SynAct Pharma AB | 228.01 Million SEK | -451.881% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -4601.988% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -5698.278% |
| LIDDS AB (publ) | 17.65 Million SEK | -7027.686% |
| Lipum AB (publ) | 12.11 Million SEK | -10291.354% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 10.126% |
| Alzinova AB (publ) | 123.18 Million SEK | -921.514% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -427.898% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -14783.418% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -1376.519% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -8363.199% |
| Simris Alg AB (publ) | 174.55 Million SEK | -620.927% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -479.803% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | -92.56% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -1345.233% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -4314.175% |